Merck Past Earnings Performance

Past criteria checks 5/6

Merck has been growing earnings at an average annual rate of 2.1%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 9.5% per year. Merck's return on equity is 27.3%, and it has net margins of 19.2%.

Key information

2.1%

Earnings growth rate

2.3%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	9.5%
Return on equity	27.3%
Net Margin	19.2%
Next Earnings Update	04 Feb 2025

Recent past performance updates

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Nov 15

Recent updates

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Nov 15

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Nov 14

Merck: An Undervalued Dividend Machine

Nov 07

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Oct 25

Revenue & Expenses Breakdown

How Merck makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:MRK Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	63,174	12,148	10,050	19,444
30 Jun 24	62,480	13,736	9,847	17,739
31 Mar 24	61,403	2,306	9,839	18,592
31 Dec 23	60,115	365	9,884	18,342
30 Sep 23	59,315	4,608	9,423	12,556
30 Jun 23	58,311	3,111	9,934	12,881
31 Mar 23	57,869	13,030	9,851	12,433
31 Dec 22	59,283	14,519	9,669	11,918
30 Sep 22	58,974	15,322	10,256	11,923
30 Jun 22	57,169	16,641	9,776	10,940
31 Mar 22	53,978	13,910	9,489	10,515
31 Dec 21	48,704	12,345	9,403	11,942
30 Sep 21	46,131	5,908	9,260	10,725
30 Jun 21	43,906	3,665	8,845	10,678
31 Mar 21	41,857	4,793	8,669	10,339
31 Dec 20	41,518	4,519	8,569	10,564
30 Sep 20	42,438	9,492	8,812	9,079
30 Jun 20	43,906	9,070	9,200	8,818
31 Mar 20	46,312	9,399	9,700	8,990
31 Dec 19	39,121	5,690	8,829	8,594
30 Sep 19	45,970	9,314	9,604	8,489
30 Jun 19	44,367	9,362	9,586	7,997
31 Mar 19	43,073	8,399	9,467	8,084
31 Dec 18	42,294	6,220	9,587	9,254
30 Sep 18	41,729	3,347	9,541	9,251
30 Jun 18	41,259	1,341	9,554	11,680
31 Mar 18	40,725	1,579	9,449	11,182
31 Dec 17	40,122	2,394	9,560	9,845
30 Sep 17	39,804	2,845	9,615	9,427
30 Jun 17	40,016	5,086	9,612	6,916
31 Mar 17	39,929	4,346	9,713	7,035
31 Dec 16	39,807	3,920	9,313	6,921
30 Sep 16	39,907	5,492	9,193	6,849
30 Jun 16	39,444	5,133	9,312	6,828
31 Mar 16	39,385	4,614	9,776	6,518
31 Dec 15	39,498	4,442	9,799	6,613
30 Sep 15	39,765	10,781	10,262	6,727
30 Jun 15	40,249	9,850	10,756	6,644
31 Mar 15	41,398	11,168	10,818	6,685
31 Dec 14	42,237	11,920	11,172	6,532
30 Sep 14	43,075	5,385	11,501	6,435
30 Jun 14	43,550	5,614	11,304	6,544
31 Mar 14	43,626	4,516	11,511	6,774
31 Dec 13	44,033	4,404	11,672	7,123

Quality Earnings: MRK has a large one-off loss of $4.4B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: MRK's current net profit margins (19.2%) are higher than last year (7.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MRK's earnings have grown by 2.1% per year over the past 5 years.

Accelerating Growth: MRK's earnings growth over the past year (163.6%) exceeds its 5-year average (2.1% per year).

Earnings vs Industry: MRK earnings growth over the past year (163.6%) exceeded the Pharmaceuticals industry 54.6%.

Merck Past Earnings Performance

Past criteria checks 5/6

Key information

Recent past performance updates

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Third quarter 2024 earnings: EPS misses analyst expectations

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

Recent updates

Third quarter dividend of US$0.81 announced

Merck & Co., Inc.'s WELIREG (Belzutifan) Approves in China for the Treatment of Adult Patients with Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Merck: An Undervalued Dividend Machine

Third quarter 2024 earnings: EPS misses analyst expectations

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

Merck Is At Support And Should Go Higher (Technical Analysis)

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Merck Appears Ready To Return To June Highs (Technical Analysis)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck's Change To Profit Guidance Provides An Opportunity

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies